Every 424B that Crescent Biopharma, Inc. (CBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIO filings page.
Crescent Biopharma, Inc. is registering for resale by selling securityholders up to 19,580,843 ordinary shares, including outstanding shares and shares issuable from pre-funded warrants and conversion of 2,890 Series A non-voting convertible preferred shares. The company’s ordinary shares trade on Nasdaq under “CBIO”; the closing price was $14.77 on July 29, 2026.
As of June 30, 2026, Crescent reported $171.6 million in cash and cash equivalents and total assets of $182.8 million, with total liabilities of $19.5 million and shareholders’ equity of $163.3 million. The company generated $1.0 million of license revenue in the first half of 2026 and recorded a net loss of $48.1 million, driven by $37.3 million in research and development and $16.6 million in general and administrative expenses.
Crescent is a clinical-stage oncology company developing programs such as CR-001 and CR-002 under license from Paragon Therapeutics, and SKB105 (CR-003) under license from Kelun. It reported net cash used in operating activities of $28.4 million for the six months ended June 30, 2026 and expects existing cash, together with proceeds from a July 2026 underwritten offering, to fund operations for at least twelve months from issuance of these financial statements.
Crescent Biopharma, Inc. is conducting a primary offering of 8,094,793 ordinary shares and 525,897 pre-funded warrants to purchase ordinary shares at $14.50 per share and $14.499 per pre-funded warrant, for a public offering size of $124,999,479. Underwriters hold a 30-day option to buy up to 1,293,103 additional ordinary shares.
The company expects net proceeds of approximately $115.9 million (or $133.5 million if the option is fully exercised), to fund clinical development of oncology candidates CR-001, CR-002 and CR-003, CMC activities, preclinical programs, and general corporate purposes. Net tangible book value per share will rise from $6.67 to $8.40, implying dilution of $6.10 per new share at the offering price. Management preliminarily estimates cash and cash equivalents of approximately $171.6 million as of June 30, 2026, and believes existing cash plus this raise will fund projected needs into the second half of 2028.
Crescent Biopharma, Inc. is raising capital through a public offering of ordinary shares and pre-funded warrants under an effective shelf registration. The company is a clinical-stage oncology business developing its lead bispecific antibody CR-001 and antibody-drug conjugates CR-002 and CR-003 in Phase 1/2 trials.
The offering consists of newly issued ordinary shares listed on Nasdaq Capital Market under “CBIO” and, in lieu of shares for some investors, pre-funded warrants priced at the share offering price minus $0.001, with a $0.001 exercise price. The warrants are exercisable at any time until fully exercised, subject to ownership caps, but will not be listed and may be illiquid.
As of June 30, 2026, Crescent estimates cash and cash equivalents of approximately $171.6 million and expects existing cash, before this raise, to fund operations into 2028. Net proceeds are intended to support clinical development of CR-001, CR-002 and CR-003, chemistry and manufacturing activities, preclinical research, and general corporate purposes. Investors face immediate and substantial dilution, with additional potential dilution from extensive outstanding options, warrants, preferred shares and a $200 million at-the-market program, alongside risks specific to the pre-funded warrants and complex U.S. tax treatment.
Crescent Biopharma is registering for resale up to 19,580,843 ordinary shares. This prospectus supplement updates the March 3, 2026 prospectus to cover resale by selling securityholders of 19,580,843 Ordinary Shares, including specified tranches held by Fairmount Healthcare Fund II L.P.
The supplement references a Form 8-K and an amendment to the Form 10-Q, notes the Nasdaq closing price of $17.69 on June 18, 2026, and reports that 27,571,935 Ordinary Shares were outstanding as of April 24, 2026 / April 7, 2026. The resale is by selling securityholders (no proceeds to the company stated here).
Crescent Biopharma, Inc. files a prospectus supplement updating its resale registration for 19,580,843 ordinary shares to permit resale or other dispositions by the identified selling securityholders. The resale amount consists of a mix of outstanding shares, pre-funded warrant shares and shares issuable on conversion of Series A preferred.
Shares outstanding were 27,571,935 as of April 24, 2026. The supplement incorporates information from Crescent’s Form 10-Q for the quarter ended March 31, 2026.
Crescent Biopharma registered 19,580,843 Ordinary Shares for resale by selling securityholders under a Form S-1 shelf registration declared effective January 15, 2026.
The registration covers up to 13,664,251 Private Placement Shares, 131,434 pre-funded warrant shares, and additional shares related to Fairmount Healthcare Fund II L.P., including outstanding shares, pre-funded warrant shares, and conversion shares. The company will not receive proceeds from resale transactions; it previously completed a Private Placement aggregating approximately $185.0 million on December 8, 2025.
Crescent Biopharma, Inc. files a prospectus supplement updating its resale prospectus to register up to 19,710,257 ordinary shares for resale by selling securityholders as described in the prospectus supplement dated February 26, 2026.
The supplement states the registered shares consist of (i) 13,664,251 outstanding shares issued in the Private Placement, (ii) 131,434 shares issuable upon exercise of pre-funded warrants, and (iii) amounts held by Fairmount Healthcare Fund II L.P., including 1,387,866 outstanding shares, 1,636,706 shares issuable upon exercise of pre-funded warrants, and 2,890,000 shares issuable upon conversion of Series A non-voting convertible preferred shares. The supplement incorporates information from the company’s Annual Report on Form 10-K filed February 26, 2026 and notes the company’s Nasdaq listing and closing share price of $12.49 on February 25, 2026.
Crescent Biopharma is registering up to 19,710,257 ordinary shares for resale by existing investors, not for a new capital raise. These “Resale Shares” include 13,664,251 shares sold in a December 8, 2025 private placement, 131,434 shares underlying related pre-funded warrants, and additional shares held by Fairmount Healthcare Fund II L.P., including stock underlying pre-funded warrants and Series A convertible preferred shares.
The company will not receive proceeds from any resale of these shares, but will receive nominal cash if the pre-funded warrants are exercised. As of December 31, 2025, Crescent had 27,556,767 ordinary shares outstanding and 2,890 Series A non-voting convertible preferred shares outstanding. Crescent is a clinical-stage oncology-focused biotechnology company developing a PD-1 x VEGF bispecific antibody (CR-001) and antibody drug conjugates, with extensive risk disclosures around its early-stage pipeline, ongoing losses, and need for future financing.